Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPRNewsWire · Oct 15, 2026
Ovid Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 3, 2026
BlackRock Inc. Takes Position in Ovid Therapeutics $OVIDDefense World · Sep 2, 2026
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?Zacks Investment Research · Aug 18, 2026
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research · Aug 13, 2026
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 13, 2026Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.12 | -$0.08 | Beat |
| May 12, 2026 | -$0.12 | -$0.12 | Beat |
| Mar 18, 2026 | -$0.10 | $0.06 | Beat |
| Nov 12, 2025 | -$0.15 | -$0.17 | Miss |
| Aug 13, 2025 | -$0.16 | -$0.06 | Beat |
| May 13, 2025 | -$0.14 | -$0.14 | Beat |